Chimeric Vaccine Stimulation Of Human Dendritic Cell Indoleamine 2, 3-Dioxygenase Occurs Via The Non-Canonical Nf-Kappa B Pathway

A chimeric protein vaccine composed of the cholera toxin B subunit fused to proinsulin (CTB-INS) was shown to suppress type 1 diabetes onset in NOD mice and upregulate biosynthesis of the tryptophan catabolic enzyme indoleamine 2, 3-dioxygenase (IDO1) in human dendritic cells (DCs). Here we demonstrate siRNA inhibition of the NF-kappa B-inducing kinase (NIK) suppresses vaccine-induced IDO1 biosynthesis as well as IKKa phosphorylation. Chromatin immunoprecipitation (ChIP) analysis of CTB-INS inoculated DCs showed that RelB bound to NF-kappa B consensus sequences in the IDO1 promoter, suggesting vaccine stimulation of the non-canonical NF-kappa B pathway activates IDO1 expression in vivo. The addition of Tumor Necrosis Factor Associated Factors (TRAF) TRAF 2, 3 and TRAF6 blocking peptides to vaccine inoculated DCs was shown to inhibit IDO1 biosynthesis. This experimental outcome suggests vaccine activation of the TNFR super-family receptor pathway leads to upregulation of IDO1 biosynthesis in CTB-INS inoculated dendritic cells. Together, our experimental data suggest the CTB-INS vaccine uses a TNFR-dependent signaling pathway of the non-canonical NF-kappa B signaling pathway resulting in suppression of dendritic cell mediated type 1 diabetes autoimmunity.